Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lotemax vs Artificial Tears in Dry Eye Disease
NCT02120079Phase 4Completed
- Sponsor
- Tufts Medical Center
- Start
- Feb 2014
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of loteprednol etabonate ophthalmic gel 0.38% in dry eye disease (DED), sponsored by Tufts Medical Center. Primary endpoint: IVCM for Density of Corneal Immune Dendritiform Cells at 6 weeks. Started Feb 2014; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02120079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02120079.